Management of factor XI deficiency in oncological liver and colorectal surgery by therapeutic plasma exchange: A case report

Pratx, Leandro Daniel Burgos; Santoro, Diego Mario; Mileo, Federico G.; Martinuzzo, Marta; Ardiles, Victoria; Santibañés, Eduardo de; Salamone, Horacio J.

doi:10.1016/j.transci.2021.103176

Cited by 4 publications

(4 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In this case report, patient did not undergo any hemostatic challenged during periods of aFXIdef, but,after the therapeutic test of reported in some cases with severe FXI congenital deficiency [10][11][12] and in cases with FXI inhibitors. 13,14 In all patient plasma samples were aFXIdef was present, neutralizing inhibitory activity was never detected.…”

Section: Evolutionmentioning

confidence: 68%

Acquired FXI deficiency in a systemic lupus erythematosus patient: Evolution and coagulation phenotypic changed to lupus anticoagulant during immunosuppressive therapy

Martinuzzo

Seehaus

López

et al. 2022

Int J Lab Hematology

Self Cite

View full text Add to dashboard Cite

Inhibitors against factor XI have been reported as alloantibodies in patients with congenital severe deficiency who received replacement therapy, 1 or less frequent as autoantibodies in patients with systemic lupus erythematosus (SLE), Rheumatoid arthritis or other autoimmune diseases, as well as neoplasm. 2-4 Rarer, few cases T A B L E 1 Laboratory data at diagnosis Tests Results 17/11/2017 Reference range or cut off points Haemoglobin (g/dl) 8.9 11.5-15.0 Creatinine (mg/dl) 0.8 mg/dl 0.5-1.2 Urea (mg/dl) 36 mg/dl 10-40 Anticardiolipin antibody IgM/IgG (MPL and GPL units) 35 /48 Low positive <20 Anti β2glycoprotein I antibody IgM/IgG (AU) 17/ 66 Low positive <15 Antinuclear antibodies (ANA) 1/1280 (homogeneous pattern) <1/80 Anti-Ro (SSA)/Anti-Sm Positive/negative Negative Anti-dsDNA Positive 1/640 Negative Rheumatoid factor UI/ml 28 <15 C3 mg/dl 38 83-177 C4 mg/dl 6 10-40 24 h proteinuria (g/L) 0.52 <0.08

show abstract

Section: Evolutionmentioning

confidence: 68%

Acquired FXI deficiency in a systemic lupus erythematosus patient: Evolution and coagulation phenotypic changed to lupus anticoagulant during immunosuppressive therapy

Martinuzzo

Seehaus

López

et al. 2022

Int J Lab Hematology

Self Cite

View full text Add to dashboard Cite

show abstract

“…Therapeutic agents available for management of FXI deficiency include FFP, FXI concentrate, antifibrinolytic agents such as ε‐aminocaproic acid or tranexamic acid, desmopressin, and low‐dose activated recombinant factor VII before surgery have been used to prevent bleeding complications 1 . Therapeutic plasma exchange and liver transplantation have also been reported to correct FXI deficiency 10–12 . A systematic review found that the most common treatment for patients with FXI deficiency undergoing surgery or invasive procedures was FXI concentrate (48.4%), followed by FFP (21.6%) 4 .…”

Section: Discussionmentioning

confidence: 99%

“…1 Therapeutic plasma exchange and liver transplantation have also been reported to correct FXI deficiency. [10][11][12] A systematic review found that the most common treatment for patients with FXI deficiency undergoing surgery or invasive procedures was FXI concentrate (48.4%), followed by FFP (21.6%). 4 However, the FXI preparations currently available in some European countries were not available in our hospital, and there are concerns about their potential thrombogenicity.…”

Section: Case Presentationmentioning

confidence: 99%

Successful use of peritoneal dialysis after abdominal surgery in a patient with factor XI deficiency: A case report

Chen

Wang

et al. 2023

Seminars in Dialysis

View full text Add to dashboard Cite

Factor XI (FXI) deficiency is a rare bleeding disorder of unpredictable severity that correlates poorly with FXI coagulation activity and that poses great challenges for perioperative hemostatic management and the dialysis methods potentially available to new end-stage renal disease (ESRD) patients. We describe an individual with both ESRD and severe FXI deficiency, who successfully underwent peritoneal dialysis (PD) after emergency abdominal surgery. In the traditional concept, recent abdominal surgery is a contraindication to PD, especially for patients with bleeding risk. However, this case report highlights that PD can still be an possible option for patients with FXI deficiency who have just undergone abdominal surgery; laparoscopic PD catheter placement offers a chance to establish PD access in patients traditionally viewed as noncandidates for this method. Careful perioperative management and fresh frozen plasma transfusion ensure successful surgery. This case should be of help to clinicians and patients considering PD in similar situations.

show abstract

“…The information on this subject comes from the case reports, case series and reviews of these publications. [7][8][9][10][11] Based on this information, as it is important to the know about the diagnosis, follow-up and treatment processes of RCD patients, we aimed to analyze RCD patients, which is rare but can be challenging when the patients have bleeding during or after surgeries and interventions, in our tertiary center.…”

mentioning

confidence: 99%

Perioperative Management of Patients with Rare Congenital Factor Deficiency

Can

2023

EJMI

View full text Add to dashboard Cite

Objectives: Fibrinogen, prothrombin, factor V, VII, X, XI, XIII and V+VIII deficiencies are defined as rare congenital factor deficiencies (RCD). Due to small number of patients and lack of data, perioperative management can be challeging. We aimed to evaluate the RCD patients who underwent surgery. Methods: Thirteen women, eight men, totally 21 patients was retrospectively analyzed. Results: Ten patients were diagnosed incidentally by investigating the bleeding tests performed before the procedure and routine bleeding tests. Two patients had diagnosed with fibrinogen disorder, one patient factor V deficiency, 9 patients factor VII deficiency, 2 patients factor X deficiency, 4 patients factor XI deficiency, 3 patients combined factor deficiency. Six patients underwent gynecological intervention, 4 patients dental procedures, 2 patients orthopedic surgery, 2 patients appendectomy, 2 patients urological intervention, one patient gastrectomy, one patient rhinoplasty, one retinal surgery, one lipoma excision, one cardiological intervention. Two of the patients were treated with only antifibrinolytic therapy before the procedure/surgery, while 19 patients were treated with replacement therapy appropriate to their disease. Ten patients were continued with replacement therapy after the procedure/surgery. None of the patients had bleeding. Conclusion: Perioperative management of patients with rare factor deficiency is crucial in terms of bleeding and related complications.

show abstract

Management of factor XI deficiency in oncological liver and colorectal surgery by therapeutic plasma exchange: A case report

Cited by 4 publications

References 13 publications

Acquired FXI deficiency in a systemic lupus erythematosus patient: Evolution and coagulation phenotypic changed to lupus anticoagulant during immunosuppressive therapy

Acquired FXI deficiency in a systemic lupus erythematosus patient: Evolution and coagulation phenotypic changed to lupus anticoagulant during immunosuppressive therapy

Successful use of peritoneal dialysis after abdominal surgery in a patient with factor XI deficiency: A case report

Perioperative Management of Patients with Rare Congenital Factor Deficiency

Contact Info

Product

Resources

About